Myeloma Manufacturers, Suppliers & Companies (Medical Specialties)
-
Research institutebased in Bangkok, THAILAND
The Regeneration Center provides comprehensive and scientifically backed stem cell treatments for numerous conditions and degenerative diseases. Through years of research and clinical applications of modern cellular therapeutics our internationally ...
-
Manufacturerbased in Utrecht, NETHERLANDS
At LAVA, we are focused on applying our expertise in gamma-delta T cell engagers. We are building a pipeline of gamma-delta bsTCEs that have applications in both solid and hematologic malignancies. Our lead program, LAVA-051, targets the tumor ...
Lava - Model 051 - Pipeline
Our lead program, LAVA-051, is a unique, humanized gamma-delta bsTCE targeting CD1d-expressing tumors, including multiple myeloma, chronic lymphocytic leukemia (CLL), and acute myeloid leukemia (AML). We have achieved preclinical proof-of-concept ...
CONTACT SUPPLIER -
Manufacturerbased in Paris, FRANCE
Oncovita is a biotech company developing a disruptive virus-derived vaccine technology to treat multiple types of cancers. Our MeasovirTM platform was developed based on the safe and highly immunogenic measles virus vaccine, a vaccine with ...
-
Technologybased in Paramus, NEW JERSEY (USA)
Starton is an emerging clinical-stage biotechnology company transforming standard of care therapies with proprietary dermal delivery technology, so people with cancer can receive continuous treatment to live better, longer. Focused on continuous ...
Model STAR-LLD in MM - Two Continuous Delivery Systems: Subcutaneous and Transdermal
STAR-LLD is in development in two continuous delivery systems: subcutaneous and transdermal. STAR-LLD is in development for new multiple myeloma indications for lenalidomide and achievement of superiority versus oral lenalidomide in maintenance ...
CONTACT SUPPLIER -
Technologybased in Nangang Distric, TAIWAN
We are a clinical-stage specialty pharmaceutical company dedicated to the development and commercialization of best-in-class novel nanomedicines that combine our proprietary lipid-assembled drug delivery platform with approved active pharmaceutical ...
-
Manufacturerbased in Hangzhou City, CHINA
Cnpair Biotech Co., Ltd. is a professional provider which concentrates on IVD core materials, including antibodies and proteins, and we are dedicated to developing and delivering highly competitive antibodies and proteins with outstanding ...
-
Manufacturerbased in Mont-Saint-Guibert, BELGIUM
Celyad Oncology is a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer. We are developing a diversified pipeline of allogeneic and autologous CAR T cell ...
Celyad - Model CYAD-211 - Allogeneic CAR T Candidate
CYAD-211 is a short hairpin RNA (shRNA)-based allogeneic CAR T candidate for the treatment of relapsed or refractory multiple myeloma (r/r MM). CYAD-211 is engineered to co-express a B-cell maturation antigen (BCMA) chimeric antigen receptor and a ...
CONTACT SUPPLIER -
Technologybased in South San Francisco, CALIFORNIA (USA)
Sutro Biopharma is a clinical stage company pioneering a compelling and unique way of discovering, developing and manufacturing therapeutics. Our focus is aimed primarily on next-generation cancer therapeutics – antibody drug conjugates, bispecific ...
-
Technologybased in San Diego, CALIFORNIA (USA)
We apply cutting-edge science to create innovative therapies that will improve the lives of those who suffer from cancer, intractable pain and COVID-19. Cancer is genetically diverse, highly adaptive, constantly mutating and virtually invisible to ...
-
Manufacturerbased in Gosselies, BELGIUM
SYnAbs was founded in 2015 as a Belgian spin-off of the Catholic University of Louvain (UCL), based on the work of Prof. Hervé Bazin, the inventor of the world's first rat myeloma cell line. SYnAbs' vision is to fill the gap on the marketplace for ...
SYnAbs Rat-LOU Monoclonal Antibodies
When you perform intraperitoneal injection of hapten or highly homologous antigens in mouse species, most of the time your project is going to fail. Due to poor immunogenic properties and low molecular weight, your antigen is going to be eliminated ...
CONTACT SUPPLIER
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you